Literature DB >> 8351601

Percutaneous endoscopic gastrostomy (PEG) in cancer patients.

R T Zera1, H R Nava, J I Fischer.   

Abstract

Ninety-nine cancer patients underwent PEG placement attempt at Rosewell Park Cancer Institute between January 1, 1985, and December 1, 1987. Ninety-eight of these were successful and were retrospectively reviewed to determine if cancer patients constitute a high-risk group for PEG placement. Procedure-related mortality was 2% and morbidity was 19%. Morbidity of 17% was noted at less than 30 days and 2% had late complications. Six complications were considered serious with peritonitis in 3 and tube loss in 3 patients; an additional 4 patients had a failure of adequate GI tract decompression which was the indication for their PEG placement. Ascites was a major factor in morbidity with 4 of 5 patients with ascites having complications including the 2 deaths. Overall major morbidity was not increased in cancer patients without ascites including a group of patients with carcinomatosis (18 patients) and 22 patients requiring preoperative dilatation and/or tumor ablative procedures. We conclude that morbidity in cancer patients is not increased if one excludes those with ascites from the procedure.

Entities:  

Mesh:

Year:  1993        PMID: 8351601     DOI: 10.1007/bf00725945

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  PEG feeding tube migration and erosion into the abdominal wall.

Authors:  A M Nelson
Journal:  Gastrointest Endosc       Date:  1989 Mar-Apr       Impact factor: 9.427

2.  PEG feeding tube migration impaction in the abdominal wall.

Authors:  H I Schwartz; R I Goldberg; J S Barkin; R S Phillips; A Land; M Hecht
Journal:  Gastrointest Endosc       Date:  1989 Mar-Apr       Impact factor: 9.427

3.  Endoscopic versus operative gastrostomy: final results of a prospective randomized trial.

Authors:  G V Stiegmann; J S Goff; D Silas; N Pearlman; J Sun; L Norton
Journal:  Gastrointest Endosc       Date:  1990 Jan-Feb       Impact factor: 9.427

4.  Spontaneous tube extrusion following percutaneous endoscopic gastrostomy.

Authors:  K M Behrle; A A Dekovich; H V Ammon
Journal:  Gastrointest Endosc       Date:  1989 Jan-Feb       Impact factor: 9.427

5.  Complication of the Russell PEG method.

Authors:  B Banerjee; J Moore
Journal:  Gastrointest Endosc       Date:  1989 Mar-Apr       Impact factor: 9.427

6.  Necrotizing fasciitis following percutaneous endoscopic gastrostomy.

Authors:  D R Cave; W R Robinson; E A Brotschi
Journal:  Gastrointest Endosc       Date:  1986-08       Impact factor: 9.427

7.  Percutaneous endoscopic gastrostomy--to push or pull. A prospective randomized trial.

Authors:  R B Hogan; D C DeMarco; J K Hamilton; C O Walker; D E Polter
Journal:  Gastrointest Endosc       Date:  1986-08       Impact factor: 9.427

8.  Effect of antibiotic prophylaxis in percutaneous endoscopic gastrostomy.

Authors:  S K Jonas; S Neimark; A P Panwalker
Journal:  Am J Gastroenterol       Date:  1985-06       Impact factor: 10.864

9.  Percutaneous endoscopic gastrostomy. Indications, success, complications, and mortality in 314 consecutive patients.

Authors:  D E Larson; D D Burton; K W Schroeder; E P DiMagno
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

10.  Gastrostomy without laparotomy: a percutaneous endoscopic technique.

Authors:  M W Gauderer; J L Ponsky; R J Izant
Journal:  J Pediatr Surg       Date:  1980-12       Impact factor: 2.545

View more
  2 in total

Review 1.  Palliative percutaneous endoscopic gastrostomy placement for gastrointestinal cancer: Roles, goals, and complications.

Authors:  Matthew Mobily; Jitesh A Patel
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

2.  Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites.

Authors:  Colette Shaw; Roland L Bassett; Patricia S Fox; Kathleen M Schmeler; Michael J Overman; Michael J Wallace; Sanjay Gupta; Alda Tam
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.